BiotechTube

edoxaban tosylate + enoxaparin/unfractionated heparin + warfarin

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Deep Vein Thrombosis

Conditions

Deep Vein Thrombosis, Venous Thrombosis

Trial Timeline

Aug 1, 2012 → Mar 1, 2014

NCT ID
NCT01662908

About edoxaban tosylate + enoxaparin/unfractionated heparin + warfarin

edoxaban tosylate + enoxaparin/unfractionated heparin + warfarin is a phase 2 stage product being developed by Daiichi Sankyo for Deep Vein Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01662908. Target conditions include Deep Vein Thrombosis, Venous Thrombosis.

What happened to similar drugs?

4 of 12 similar drugs in Deep Vein Thrombosis were approved

Approved (4) Terminated (2) Active (8)
✅Dalteparin sodium injection + WarfarinPfizerApproved
✅Low Molecular Weight Heparin (dalteparin)PfizerApproved
✅ApixabanPfizerApproved
✅ClexaneSanofiApproved
🔄Apixaban + Unfractionated Heparin (UFH) + WarfarinPfizerPhase 3
🔄Enoxaparin + Placebo + Apixaban + PlaceboBristol Myers SquibbPhase 3
🔄Enoxaparin + Apixaban + Enoxaparin-matching placebo + Apixaban-matching placeboBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01662908Phase 2Completed

Competing Products

20 competing products in Deep Vein Thrombosis

See all competitors
ProductCompanyStageHype Score
Edoxaban low dose + Edoxaban high doseDaiichi SankyoPhase 1
29
Fragmin (dalteparin sodium )PfizerPre-clinical
26
FluconazolePfizerPre-clinical
26
Dalteparin sodium injection + WarfarinPfizerApproved
43
Low Molecular Weight Heparin (dalteparin)PfizerApproved
43
Apixaban + Unfractionated Heparin (UFH) + WarfarinPfizerPhase 3
40
ApixabanPfizerApproved
35
ApixabanBristol Myers SquibbPhase 2
35
Enoxaparin + Placebo + Apixaban + PlaceboBristol Myers SquibbPhase 3
40
Enoxaparin + Apixaban + Enoxaparin-matching placebo + Apixaban-matching placeboBristol Myers SquibbPhase 3
40
ApixabanBristol Myers SquibbPre-clinical
26
Enoxaparin + Apixaban + Enoxaparin-matching placebo + Apixaban-matching placeboBristol Myers SquibbPhase 3
40
EnoxaparinSanofiPre-clinical
26
ClexaneSanofiApproved
35
Idrabiotaparinux sodium + Idraparinux sodium + Avidin + Placebo (for Avidin)SanofiPhase 3
40
SanOrg34006 + LMW heparin + Unfractionated heparin + Vitamin K antagonist (VKA)SanofiPhase 3
40
Rivaroxaban (Xarelto, BAY59-7939) + Standard of careBayerPre-clinical
23
Rivaroxaban (Xarelto, BAY59-7939) + Rivaroxaban (Xarelto, BAY59-7939) + Unfractionated heparin + WarfarinBayerPhase 3
37
Rivaroxaban (Xarelto, BAY59-7939) + Recommended VTE pharmacological treatments according to international guidelinesBayerPre-clinical
23
Triptorelin Acetate 3.75mg intramuscular injectionIpsenPre-clinical
23